首页> 外国专利> Humanized anti-CD20 antibodies cause more deaths when they form a complex with CD20 than their parents'antibodies; pharmacological components; desorbents used to treat response B cell elimination; coding for polyriboses; vectors, C L Ula host; production method (branch request number: 2246-06).

Humanized anti-CD20 antibodies cause more deaths when they form a complex with CD20 than their parents'antibodies; pharmacological components; desorbents used to treat response B cell elimination; coding for polyriboses; vectors, C L Ula host; production method (branch request number: 2246-06).

机译:当与CD20形成复合物时,人源化抗CD20抗体比其父母的抗体导致更多的死亡。药理成分用于治疗反应B细胞消除的解吸剂;编码多核糖;载体,C L Ula宿主;生产方法(分支机构请求编号:2246-06)。

摘要

Anti CD 20 Antibody modified compared with murine monoclonal antibody (LY1 induces increased level of apoptosis (cell that expresses LY1; degrading Enzyme activity of Sugar and the ancientRPO, Pharmaceutical composition containing same and its uses; polinucleu00f3tido, vector, cell and Method for producing Said Antibody.
机译:与鼠类单克隆抗体相比经过修饰的抗CD 20抗体(LY1诱导凋亡水平增加(表达LY1的细胞;糖和AncientRPO的酶活性下降),包含其的药物组合物及其用途;核仁,载体,细胞和生产所述抗体。

著录项

  • 公开/公告号CL2010000822A1

    专利类型

  • 公开/公告日2011-01-07

    原文格式PDF

  • 申请/专利权人 ROCHE GLYCART AG;

    申请/专利号CL20100000822

  • 发明设计人 UMANA PABLO;MOSSNER EKKEHARD.;

    申请日2010-07-30

  • 分类号A61K39/395;A61P35/00;A61P37/00;C07K16/28;C12N15/13;C07K6/30;

  • 国家 CL

  • 入库时间 2022-08-21 18:06:59

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号